Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Return on Equity (2020 - 2025)

Historic Return on Equity for C4 Therapeutics (CCCC) over the last 6 years, with Q3 2025 value amounting to 0.73%.

  • C4 Therapeutics' Return on Equity fell 2900.0% to 0.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73%, marking a year-over-year decrease of 2900.0%. This contributed to the annual value of 0.46% for FY2024, which is 400.0% up from last year.
  • As of Q3 2025, C4 Therapeutics' Return on Equity stood at 0.73%, which was down 2900.0% from 0.6% recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Return on Equity registered a high of 0.21% during Q4 2021, and its lowest value of 0.73% during Q3 2025.
  • Moreover, its 5-year median value for Return on Equity was 0.43% (2024), whereas its average is 0.43%.
  • Data for C4 Therapeutics' Return on Equity shows a peak YoY increase of 8500bps (in 2021) and a maximum YoY decrease of -6000bps (in 2021) over the last 5 years.
  • Over the past 5 years, C4 Therapeutics' Return on Equity (Quarter) stood at 0.21% in 2021, then crashed by -97bps to 0.42% in 2022, then crashed by -36bps to 0.57% in 2023, then increased by 20bps to 0.46% in 2024, then crashed by -58bps to 0.73% in 2025.
  • Its Return on Equity was 0.73% in Q3 2025, compared to 0.6% in Q2 2025 and 0.5% in Q1 2025.